Targets › UL89
1 program from 1 company in 13 trials: 5 Phase 3, 4 Phase 2, 3 Phase 4, 1 Phase 1; Genitourinary, Infectious disease, Oncology; next expected readout Apr 2028.
Open in Phaseline: the race on UL89, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Merck & Co. (MSD) | Letermovir (MK-8228) DNA terminase inhibitor | UL89 | Phase 1 | Cytomegalovirus Prophylaxis; Kidney Transplant; CMV; Cytomegalovirus Infections … | Apr 2028 |
CMV (2) Cytomegalovirus Infections (2) Cytomegalovirus Prophylaxis (1) Kidney Transplant (1) Hematologic Malignancy (1) Cytomegalovirus Infection (1) Hematopoietic and Lymphoid Cell Neoplasm (1) Pregnant Women (1) Relapsed Refractory Multiple Myeloma (RRMM) (1) CMV Viremia (1) Cell Therapy (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.